Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Clin Cancer Res. 2018 May 29;24(17):4256–4270. doi: 10.1158/1078-0432.CCR-17-3645

Figure 4.

Figure 4.

Elatol treatment induces ATF4 expression, not mediated by the UPR. A) Cell viability of SNU-398 cells measured after 72-hour treatment with translation inhibitors silvestrol, rapamycin or elatol. Mean ± SEM n=4. B) Western blot showing protein expression SNU-398 cells treated with DMSO (D), 200 nM rapamycin (R), 100 nM silvestrol (S) or 1 μM elatol (E) for 16 hours. Representative images. C) Time course showing protein expression in DLBCL cell lines following elatol treatment. Representative images. n=2. D) Cell death measured by flow cytometry following annexin V staining in DLBCL cell lines treated with indicated inhibitors with or without the combination of the PERK inhibitor GSK2606414 for 24 hours. Mean ± SEM n=3. * = p< 0.05, ** = p<0.001. E) Western blot showing protein expression in cells treated for four hours with DMSO, 100nM silvestrol, 5 μM elatol or 5 μM tunicamycin with or without the combination with the PERKi. Representative images. n=3.